Bayer Healthcare received European Commission approval for EYLEA to treat Macular Edema secondary to Central Retinal Vein Occlusion, the second indication for which the drug has been cleared. The clearance was granted after two phase III studies that showed significant visual acuity improvement with EYLEA.
EYLEA was first approved to treat wet age-related Macular Degeneration.
More Articles on Ophthalmology:
Ophthalmologist Dr. George Primbs Recognized for Community Service
Glaucoma, Cataract Specialist Dr. Charles Weber Joins The Eye Institute of Utah
Eye Care Product Maker Akorn to Acquire Hi-Tech Pharmacal for $640M